Thomasville National Bank Purchases New Shares in Gilead Sciences, Inc. $GILD

Key Points

• Thomasville National Bank acquired 91,822 Gilead Sciences shares during the second quarter, worth approximately $11.6 million. Institutional investors and hedge funds collectively own 83.67% of the company.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year and above analyst expectations, while its adjusted loss per share beat consensus estimates. The company also declared a quarterly dividend of $0.82, representing a 2.4% annualized yield.
• Analyst sentiment remains broadly positive, with 24 Buy ratings and five Holds producing a “Moderate Buy” consensus and a $158.04 price target. However, insiders sold 82,000 shares worth $10.6 million over the past three months.

Thomasville National Bank bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 91,822 shares of the biopharmaceutical company's stock, valued at approximately $11,601,000.

Several other hedge funds have also recently modified their holdings of the stock. Sterling Investment Counsel LLC increased its stake in Gilead Sciences by 2.3% during the 2nd quarter. Sterling Investment Counsel LLC now owns 9,013 shares of the biopharmaceutical company's stock worth $1,139,000 after buying an additional 205 shares in the last quarter. Ticino Wealth raised its holdings in shares of Gilead Sciences by 12.2% during the second quarter. Ticino Wealth now owns 7,756 shares of the biopharmaceutical company's stock valued at $980,000 after acquiring an additional 845 shares during the last quarter. Royal Fund Management LLC lifted its position in shares of Gilead Sciences by 37.2% in the second quarter. Royal Fund Management LLC now owns 2,573 shares of the biopharmaceutical company's stock valued at $325,000 after acquiring an additional 697 shares in the last quarter. Wellspring Financial Advisors LLC lifted its position in shares of Gilead Sciences by 5.4% in the second quarter. Wellspring Financial Advisors LLC now owns 4,213 shares of the biopharmaceutical company's stock valued at $532,000 after acquiring an additional 216 shares in the last quarter. Finally, Fortitude Family Office LLC boosted its stake in shares of Gilead Sciences by 13.7% in the second quarter. Fortitude Family Office LLC now owns 690 shares of the biopharmaceutical company's stock worth $87,000 after acquiring an additional 83 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider owned 124,234 shares of the company's stock, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer directly owned 592,133 shares in the company, valued at $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 82,000 shares of company stock worth $10,641,790. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 0.1%

Shares of NASDAQ GILD opened at $135.87 on Thursday. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The business's 50 day moving average is $129.75 and its two-hundred day moving average is $136.42. Gilead Sciences, Inc. has a 52-week low of $108.46 and a 52-week high of $157.29. The firm has a market cap of $168.47 billion, a price-to-earnings ratio of -50.89 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.01 earnings per share. Research analysts predict that Gilead Sciences, Inc. will post -0.53 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is presently -122.85%.

Analysts Set New Price Targets

GILD has been the subject of a number of research reports. HSBC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Leerink Partners lowered shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $146.00 to $127.00 in a research report on Tuesday, July 21st. Morgan Stanley cut their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating for the company in a report on Monday, July 27th. Barclays decreased their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 29th. Finally, Needham & Company LLC restated a "buy" rating and issued a $170.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. Twenty-four analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $158.04.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead is partnering with Nucleai to deploy AI-powered tissue analytics across its global antibody-drug conjugate programs. The technology could accelerate biomarker discovery, standardize tumor-sample analysis and improve precision-oncology development, potentially strengthening Gilead’s longer-term pipeline. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Gilead exercised an option to exclusively license a preclinical bispecific program from MacroGenics, triggering a $10 million payment to its partner. The move expands Gilead’s oncology assets and signals continued investment in potential next-generation cancer treatments, although the program remains early stage. MacroGenics Announces $10 Million Milestone Following Gilead License
• Positive Sentiment: Analysts cited a consensus price target of $158.04, indicating potential upside relative to recent trading levels and continued confidence among covering analysts. Gilead Receives $158.04 Consensus Target Price
• Positive Sentiment: Gilead’s second-quarter revenue rose approximately 10% year over year to $7.8 billion and exceeded expectations. The reported loss was primarily affected by an $11.2 billion one-time acquired in-process research and development write-off, while adjusted results were better than consensus. GILD Attractive Biotech Stock With Solid Base Revenue Growth
• Neutral Sentiment: Unusually heavy call-option buying points to increased bullish trading interest, but options activity is speculative and does not by itself change Gilead’s fundamentals.
• Neutral Sentiment: Coverage of Gilead’s second-quarter earnings call may provide additional details on pipeline progress and management priorities, though no specific new financial catalyst was provided in the supplied report. Analyst Questions From Gilead’s Q2 Earnings Call
• Negative Sentiment: Erste Group Bank slightly reduced its FY2026 EPS forecast to a $0.75 loss from a $0.74 loss and trimmed its FY2027 estimate to $9.57 from $9.59. Although the changes are small, they indicate mildly softer expectations and contrast with the $0.50 consensus loss forecast for the current year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source